Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating fremanezumab (TEV-48125) for prevention of episodic cluster headache was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Episodic Cluster Headache

Drugs mentioned

• Fremanezumab (fremanezumab)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Episodic Cluster Headache | Phase 3 | Status: TERMINATED | Results posted: 2020-04-13